What Are the Possible Side Effects of Ozempic?

Ozempic (semaglutide) causes gastrointestinal side effects in a large share of people who take it, with nausea, vomiting, diarrhea, and constipation being the most frequently reported problems. But the side-effect profile extends well beyond an upset stomach. Depending on your dose, how long you take the drug, and your individual health history, semaglutide can affect your gallbladder, pancreas, eyes, body composition, and possibly your mood. Some of these effects are common and manageable; others are rare but serious enough to need medical attention.

The Gut Problems That Most People Experience

Gastrointestinal symptoms dominate the side-effect picture. A meta-analysis of randomized controlled trials across several GLP-1 receptor agonists found that roughly 23% of participants experienced nausea, about 9% had vomiting, 13% developed diarrhea, and around 7% reported constipation, all at rates significantly higher than placebo.¹ A pharmacovigilance study drawing on the FDA’s adverse event database confirmed the same pattern, with nausea far and away the most commonly filed complaint, followed by vomiting and diarrhea.²

These symptoms tend to be worst during the first few weeks and during dose increases. Ozempic is prescribed on an escalating schedule, starting at a low dose and stepping up over several months, partly to give the gut time to adjust. Most people find that the nausea and other symptoms fade as their body acclimates, but for some the problems persist long enough to cause discontinuation. Among the GLP-1 drugs compared head to head, semaglutide carries the highest risk ratios for vomiting and constipation specifically, while a newer competitor (tirzepatide) edges it out for nausea and diarrhea risk.¹ In practice, a real-world comparison found no significant difference in overall gastrointestinal side-effect rates between semaglutide and tirzepatide, suggesting the two drugs are roughly in the same ballpark for gut discomfort.³

When Stomach Problems Become Something More Serious

For most people, nausea and occasional vomiting are annoying but not dangerous. In rarer cases, though, semaglutide’s effect on the digestive system can tip into territory that requires medical intervention. Gastroparesis, a condition where the stomach empties abnormally slowly, has been reported in patients on semaglutide. In one published case, a woman presented with persistent nausea and was found to have retained food in her stomach more than 24 hours after eating, despite two separate endoscopies. After ruling out diabetes, autoimmune causes, and physical obstructions, her gastroenterology team attributed the gastroparesis to semaglutide and recommended she stop taking it.⁴

A narrative review of GLP-1 receptor agonist safety noted that accumulating evidence has identified additional serious gastrointestinal complications including gastroparesis and bowel obstruction, which may warrant caution in people who are already susceptible to motility problems.⁵ These serious complications remain uncommon, but they are worth knowing about because the warning signs (persistent vomiting, severe bloating, inability to keep food down for extended periods) can overlap with the more benign side effects people are told to expect.

Gallbladder and Biliary Problems

Gallstones and gallbladder inflammation are an underappreciated risk of Ozempic and its drug class. A systematic review and meta-analysis of 76 randomized controlled trials found that people taking GLP-1 receptor agonists had a 37% higher relative risk of developing gallbladder disease compared with those not taking them, with particular increases in gallstone formation and cholecystitis (inflammation of the gallbladder).⁶ The risk climbs with higher doses and longer treatment durations, and it is especially pronounced when semaglutide is used for weight loss rather than diabetes management. One meta-analysis found the risk more than doubled in weight-loss trials specifically.⁷

Two mechanisms are thought to be at work. First, GLP-1 receptor agonists appear to inhibit gallbladder motility and delay gallbladder emptying, allowing bile to sit and form stones. Second, rapid weight loss itself is a well-established risk factor for gallstones, and since these drugs produce substantial weight loss, the two effects compound each other.⁸ If you develop sudden pain in your upper right abdomen, especially after eating fatty food, that is the classic gallbladder warning sign and something to raise with your doctor promptly.

Pancreatitis

Pancreatitis (inflammation of the pancreas) showed up as one of the more frequently reported serious events in the FDA’s adverse event database for semaglutide.² The meta-analysis of GLP-1 receptor agonist trials estimated pancreatitis occurred in roughly 1% of participants, at about twice the rate seen with placebo.¹ Although 1% sounds low, pancreatitis is a serious condition that can become life-threatening.

A case report described a patient who had been on semaglutide for four years and developed severe acute pancreatitis after a dose increase from 0.25 to 0.5 mg weekly. The patient had none of the typical risk factors for pancreatitis (heavy drinking, gallstones), and the case ultimately proved fatal. The authors suggested a potential link between long-term use, dose changes, and severe pancreatitis.⁹ Individual case reports cannot prove causation, but they do reinforce that sudden severe abdominal pain radiating to the back, especially after a dose increase, deserves urgent medical evaluation.

Muscle and Lean Mass Loss

When you lose weight on Ozempic, not all of it comes from fat. A systematic review of clinical trials found that the proportion of lean mass lost as part of total weight loss ranged from nearly 0% to as much as 40%, with larger trials tending to show more notable lean mass reductions.¹⁰ A real-world study of compounded semaglutide treatment put more specific numbers on it: participants lost an average of about 2.7 kg of fat mass but also about 1.4 kg of lean mass, including roughly 0.9 kg of skeletal muscle mass.¹¹

There is a silver lining in the data, though. Even as people lost some lean mass in absolute terms, the proportion of their total body weight made up of lean tissue actually went up, because they were losing fat faster than muscle. Still, for older adults or anyone already at risk of sarcopenia (age-related muscle loss), even modest muscle loss matters for strength, balance, and bone health. Resistance training while on the drug is widely recommended to help preserve lean mass, though the degree to which exercise can fully offset the effect is still being studied.

Facial Volume Loss and “Ozempic Face”

One of the more visible and widely discussed cosmetic effects of semaglutide is what the media has dubbed “Ozempic face,” a gaunt, prematurely aged appearance caused by rapid loss of facial fat. Researchers describe it as a combination of fat and muscle volume loss, collagen and elastin breakdown, and excess sagging skin in the face.¹² The phenomenon is not unique to semaglutide; any rapid, significant weight loss can hollow out the face. But because Ozempic produces faster weight loss than most people achieve through diet alone, the facial changes can seem sudden and dramatic.

The face does not regain lost volume easily. Fat pads in the midface and around the temples that deflate during weight loss do not always refill, even if weight is regained. Cosmetic dermatologists report a growing number of patients seeking dermal fillers and other treatments to address the issue, which underscores that this is a real and persistent concern for many users, not just a tabloid curiosity.

Thyroid Cancer Concerns

Ozempic’s label carries a boxed warning about thyroid C-cell tumors based on findings in rodents. This warning understandably alarms people, but the human evidence so far is reassuring. A systematic literature review that pooled data from ten studies found that thyroid cancer incidence among semaglutide users was very low, with isolated cases of papillary and medullary thyroid carcinoma each making up less than 1% of their study populations.¹³ A separate narrative review of incretin-based therapies likewise concluded that human evidence did not demonstrate an increased risk of thyroid malignancy.¹⁴

The disconnect between the rodent data and the human data likely comes down to biology. Rodents have far more GLP-1 receptors on their thyroid C-cells than humans do, making them much more susceptible to this effect. That said, people with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 should not use Ozempic, and that restriction remains firmly in place regardless of the population-level data.

Eye-Related Complications in People With Diabetes

If you have diabetes and preexisting retinopathy, semaglutide deserves extra caution around your eyes. Clinical trial data from the SUSTAIN-6 cardiovascular outcomes trial revealed a higher incidence of diabetic retinopathy complications with semaglutide, particularly in patients who already had retinopathy and who experienced rapid drops in blood sugar levels.¹⁵ This “early worsening” phenomenon is not unique to semaglutide; it has been observed with insulin therapy and other treatments that quickly improve blood sugar control. The retina, adapted to a high-sugar environment, reacts poorly to the abrupt change.

Real-world pharmacovigilance data confirmed that subcutaneous semaglutide injections had a higher frequency of reported retinal complications, including diabetic retinopathy events, ischemic optic neuropathy, retinal detachment, retinal tears, and retinal hemorrhage.¹⁶ For people without diabetes or without preexisting eye disease, the concern is much lower. But if you do have diabetic retinopathy, your eye doctor should be in the loop before you start Ozempic, and more frequent retinal screenings during the early months of treatment are a good idea.

Blood Sugar Drops and Hypoglycemia Risk

Ozempic by itself rarely causes dangerously low blood sugar. The drug stimulates insulin release in a glucose-dependent way, meaning it only boosts insulin when blood sugar is elevated. The real hazard arises when semaglutide is combined with other diabetes medications that push blood sugar down independently. Hypoglycemia can occur when these agents are used with sulfonylureas or insulin.¹⁷ If you are on one of those medications and starting Ozempic, your doctor will likely reduce the dose of the other drug to prevent dangerous lows.

Depression and Suicidality Signals

Mental health effects are an area of active investigation and some controversy. A disproportionality analysis of the FDA’s adverse event database found statistically significant signals for both depression and suicide or self-injury events with semaglutide specifically, with reporting odds roughly 1.9 times higher for depression and 1.7 times higher for suicide-related events compared to baseline reporting rates.¹⁸ Notably, neither liraglutide nor tirzepatide showed the same signals in this analysis.

A European pharmacovigilance review painted a slightly broader picture, identifying depression as the most commonly reported psychiatric adverse event across GLP-1 receptor agonists as a class, followed by anxiety and suicidal ideation. Women accounted for about 65% of these psychiatric reports.¹⁹

A few important caveats here. Pharmacovigilance databases capture voluntary reports, not controlled trial outcomes, so they can detect signals but cannot prove that semaglutide causes depression. People who use weight-loss medications may already be at higher risk for mood disorders for other reasons. And there is a massive reporting bias: once regulators publicly investigate a possible link, reports pour in. Still, these signals are strong enough that the European Medicines Agency has reviewed the issue, and anyone with a history of depression or suicidal thoughts should discuss this with their prescriber before starting.

Nutritional Deficiencies

A less dramatic but potentially insidious side effect involves nutritional shortfalls. When your appetite drops sharply and you are eating far less food, you inevitably take in fewer vitamins and minerals. The persistent gastrointestinal side effects can further compromise nutrient absorption and worsen the risk of deficiency.²⁰ This matters because a joint advisory from four major medical and nutrition organizations specifically called out the need for nutritional monitoring during GLP-1 therapy.

In the most extreme cases, the appetite suppression and GI symptoms from semaglutide have contributed to Wernicke’s encephalopathy, a brain condition caused by severe thiamine (vitamin B1) deficiency. A systematic review collected case reports of this complication arising in the context of semaglutide treatment for obesity.²¹ Wernicke’s encephalopathy is rare, but it highlights a broader point: if you are barely eating and frequently vomiting on Ozempic, you should be proactive about getting basic bloodwork done and considering supplementation.

Skin and Injection-Site Reactions

Ozempic is injected subcutaneously once a week, and injection-site reactions like redness, swelling, or itching are among the milder side effects. Beyond the injection site, reported cutaneous events include hypersensitivity reactions, panniculitis (inflammation of the fat layer under the skin), and alopecia (hair loss or thinning). More unusual immune-mediated skin conditions such as bullous pemphigoid and vasculitis have also been reported, though these appear to be quite rare. Hair loss in particular has gotten attention on social media, and while it is plausible given the nutritional deficits and metabolic shifts involved in rapid weight loss, controlled data specifically linking semaglutide to alopecia at a higher rate than weight loss alone are still limited.

Risks Around Surgery and Anesthesia

One of Ozempic’s therapeutic mechanisms, slowing gastric emptying, becomes a safety problem in the operating room. Because the stomach empties more slowly, patients on semaglutide can have residual food in their stomachs even after following standard pre-surgical fasting instructions. This creates a risk of pulmonary aspiration, where stomach contents are inhaled into the lungs during anesthesia, a potentially life-threatening event.²² Several anesthesiology societies have issued guidance recommending that patients hold their semaglutide dose for at least one to three weeks before scheduled surgery, though the exact timeline varies. If you are on Ozempic and have a procedure coming up, bring it up with both your surgeon and your anesthesiologist well in advance.

Fertility, Pregnancy, and Reproductive Considerations

Semaglutide sits in an unusual spot when it comes to reproduction. On one hand, by driving weight loss and improving metabolic health, it can restore regular ovulation in women who previously had irregular cycles, sometimes leading to unplanned pregnancies. Many women who were told they might struggle to conceive have become pregnant while on the drug.²³ On the other hand, animal studies at high doses showed fetal harm, including skeletal abnormalities, growth restriction, and embryonic death, which is why manufacturers recommend stopping the drug at least two months before a planned pregnancy.²⁴

Human data, while still limited, is more encouraging than the animal studies. The largest prospective cohort looking at first-trimester exposure found no increased risk of congenital anomalies or pregnancy loss, and several smaller cohort studies and case series have reached similar conclusions.²⁴ A separate review also found no significant pattern of birth defects in human studies, though the authors noted that no information on maternal blood sugar control or diabetic fetopathy was available.²³ The bottom line from reproductive safety experts is cautious reassurance for accidental early exposure but a clear recommendation to discontinue Ozempic before trying to conceive, given the remaining gaps in the evidence.²⁵

What Happens When You Stop Taking Ozempic

Weight regain after discontinuation is one of the most consistent findings in the semaglutide literature. The STEP 1 trial extension followed participants after they stopped taking the drug and found that, on average, they regained about 11.6 percentage points of the weight they had lost within a year of stopping. Most of the cardiometabolic improvements that had come with the weight loss, including better blood pressure, cholesterol, and blood sugar markers, also drifted back toward pre-treatment levels.²⁶

A retrospective cohort study looking at patients switched from semaglutide to less potent GLP-1 drugs found a similar pattern: some patients gained weight and saw their blood sugar control deteriorate, suggesting that alternative GLP-1 medications may not fully replicate semaglutide’s effects.²⁷ This does not mean everyone regains all the weight; individual outcomes vary. But it does mean that Ozempic works best as an ongoing treatment, not a temporary fix, and that planning for what happens after discontinuation should be part of the conversation with your prescriber from the start.